<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ERGOLOID MESYLATES- dihydroergocornine mesylate, dihydroergocristine mesylate, dihydro-.alpha.-ergocryptine mesylate and dihydro-.beta.-ergocryptine mesylate tablet </strong><br>Carilion Materials Management<br></p></div>
<h1>ERGOLOID MESYLATES TABLETS USP (ORAL)
        <br><br>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Each tablet for oral use contains ergoloid mesylates USP; a mixture of the methanesulfonate salt of the following hydrogenated alkaloids:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1344cf98-7d79-4ab4-9a63-2e632d9afbd4&amp;name=ergoloid-01.jpg"></p>
<table width="55%">
<col align="left" valign="middle" width="50%">
<col align="left" valign="middle" width="50%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left"></td>
<td align="center">R</td>
</tr>
<tr>
<td align="left">Dihydroergocornine</td>
<td class="Toprule" align="left">-CH(CH )
                                        <span class="Sub">3</span><span class="Sub">2</span>
</td>
</tr>
<tr>
<td align="left">Dihydroergocristine</td>
<td align="left">-CH C H
                                        <span class="Sub">2</span><span class="Sub">6</span><span class="Sub">5</span>
</td>
</tr>
<tr>
<td align="left">Dihydro-α-ergocryptine</td>
<td align="left">-CH CH(CH )
                                        <span class="Sub">2</span><span class="Sub">3</span><span class="Sub">2</span>
</td>
</tr>
<tr class="Botrule Last">
<td align="left">Dihydro-β-ergocryptine</td>
<td align="left">-CH(CH )CH CH
                                        <span class="Sub">3</span><span class="Sub">2</span><span class="Sub">3</span>
</td>
</tr>
</tbody>
</table>
<p>C H N O • CH O S (dihydroergocornine mesylate)    659.79
                            <span class="Sub">31</span><span class="Sub">41</span><span class="Sub">5</span><span class="Sub">5</span><span class="Sub">4</span><span class="Sub">3</span><br></p>
<p>C H N O • CH O S (dihydroergocristine mesylate)    707.84
                            <span class="Sub">35</span><span class="Sub">41</span><span class="Sub">5</span><span class="Sub">5</span><span class="Sub">4</span><span class="Sub">3</span><br></p>
<p>C H N O • CH O S (dihydro-α-ergocryptine mesylate)    673.82
                            <span class="Sub">32</span><span class="Sub">43</span><span class="Sub">5</span><span class="Sub">5</span><span class="Sub">4</span><span class="Sub">3</span><br></p>
<p>C H N O • CH O S (dihydro-β-ergocryptine mesylate)    673.82
                            <span class="Sub">32</span><span class="Sub">43</span><span class="Sub">5</span><span class="Sub">5</span><span class="Sub">4</span><span class="Sub">3</span><br></p>
<table width="50%">
<col align="left" valign="middle" width="65%">
<col align="right" valign="middle" width="35%">
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>exists as a mixture of and isomers in a ratio of 2:1
                                            <span class="Underline">alpha</span><span class="Underline">beta</span>
</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First Toprule">
<td align="left"></td>
<td align="right"><span class="Underline">1 mg</span></td>
</tr>
<tr>
<td align="left">Dihydroergocristine mesylate</td>
<td align="right">0.333 mg</td>
</tr>
<tr>
<td align="left">Dihydroergocornine mesylate</td>
<td align="right">0.333 mg</td>
</tr>
<tr class="Botrule Last">
<td align="left">Dihydroergocryptine mesylate
                                        <a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td align="right">0.333 mg</td>
</tr>
</tbody>
</table>
<p>Inactive ingredients for oral tablets are: butylated hydroxyanisol, hydrogenated vegetable oil, lactose, mannitol, polyvinyl pyrrollidone, corn starch, stearic acid and talc.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">There is no specific evidence which clearly establishes the mechanism by which ergoloid mesylates preparations produce mental effects, nor is there conclusive evidence that the drug particularly affects <span class="product-label-link" type="condition" conceptid="4278243" conceptname="Cerebral arteriosclerosis">cerebral arteriosclerosis</span> or cerebrovascular insufficiency.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="section-3.1"></a><p></p>
<h2>Pharmacokinetic Properties</h2>
<p class="First">Pharmacokinetic studies have been performed in normal volunteers with the help of radiolabelled drug as well as employing a specific radioimmunoassay technique. From the urinary excretion quotient of orally and intravenously administered tritium-labelled ergoloid mesylates the absorption of ergoloid was calculated to be 25%. Following oral administration, peak levels of 0.5 ngEq/mL/mg were achieved within 1.5–3 hr. Bioavailability studies with the specific radioimmunoassay confirm that ergoloid is rapidly absorbed from the gastrointestinal tract, with mean peak levels of 0.05–0.13 ng/mL/mg (with extremes of 0.03 and 0.18 ng/mL/mg) achieved within 0.6–1.3 hr (with extremes of 0.4 and 2.8 hr). The finding of lower peak levels of ergoloid compared to the total drug-metabolite composite is consistent with a considerable first pass liver metabolism, with less than 50% of the therapeutic moiety reaching the systemic circulation. The elimination of radioactivity, representing ergoloid plus metabolites bearing the radiolabel, was biphasic with half-lives of 4 and 13 hr. The mean half-life of unchanged ergoloid in plasma is about 2.6–5.1 hr; after 3 half-lives ergoloid plasma levels are less than 10% of radioactivity levels, and by 24 hr no ergoloid is detectable.</p>
<p>Bioequivalence studies were performed comparing ergoloid mesylates oral tablets (administered orally) with ergoloid mesylates sublingual tablets (administered sublingually). The oral tablet and sublingual tablet were shown to be bioequivalent.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS</h1>
<p class="First">A proportion of individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity (i.e., cognitive and interpersonal skills, mood, self-care, apparent motivation) can experience some symptomatic relief upon treatment with ergoloid mesylates preparations. The identity of the specific trait(s) or condition(s), if any, which would usefully predict a response to ergoloid mesylates therapy is not known. It appears, however, that those individuals who do respond come from groups of patients who would be considered clinically to suffer from some ill-defined process related to aging or to have some underlying dementing condition (i.e., primary progressive <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, Alzheimer's <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, senile onset, multi-infarct <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>).</p>
<p>Before prescribing ergoloid mesylates, the physician should exclude the possibility that the patient's signs and symptoms arise from a potentially reversible and treatable condition. Particular care should be taken to exclude <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span> and dementiform illness secondary to systemic disease, primary neurological disease, or primary disturbance of mood. Ergoloid mesylates preparations are not indicated in the treatment of acute or chronic <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, regardless of etiology (see ).
                            <span class="Italics"><a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a></span></p>
<p>The decision to use ergoloid mesylates in the treatment of an individual with a symptomatic decline in mental capacity of unknown etiology should be continually reviewed since the presenting clinical picture may subsequently evolve sufficiently to allow a specific diagnosis and a specific alternative treatment. In addition, continued clinical evaluation is required to determine whether any initial benefit conferred by ergoloid mesylates therapy persists with time.</p>
<p>The efficacy of ergoloid mesylates was evaluated using a special rating scale known as the SCAG (Sandoz Clinical Assessment-Geriatric). The specific items on this scale on which modest but statistically significant changes were observed at the end of twelve weeks include: mental alertness, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, recent memory, orientation, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, self-care, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>/<span class="product-label-link" type="condition" conceptid="4029621" conceptname="Fear">fears</span>, cooperation, sociability, appetite, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, bothersome(ness), and an overall impression of clinical status.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="CONTRAINDICATIONS"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Ergoloid mesylates preparations are contraindicated in individuals who have previously shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug. Ergoloid mesylates preparations are also contraindicated in patients who have <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, acute or chronic, regardless of etiology.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"><span class="Italics">Practitioners are advised that because the target symptoms are of unknown etiology, careful diagnosis should be attempted before prescribing ergoloid mesylates preparations.</span></p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Ergoloid mesylates preparations have not been found to produce serious side effects. Transient <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and gastric disturbances have been reported. Ergoloid mesylates preparations do not possess the vasoconstrictor properties of the natural ergot alkaloids.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">1 mg three times a day.</p>
<p>Alleviation of symptoms is usually gradual and results may not be observed for 3–4 weeks.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">NDC:68151-2780-0 in a PACKAGE of 1 TABLETS</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-9.1"></a><p></p>
<h2></h2>
<p class="First">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]
                                    <br></p>
<p>DISPENSE IN TIGHT, LIGHT-RESISTANT CONTAINER.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10"></a><p></p>
<h1></h1>
<p class="First">Manufactured by: MUTUAL PHARMACEUTICAL CO., INC. Philadelphia, Pa 19124 USA
                            <br><br></p>
<p>Rev 01, January 2009</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-11"></a><p></p>
<h1>Ergoloid Mesylates 1 MG Tab</h1>
<div class="Figure"><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1344cf98-7d79-4ab4-9a63-2e632d9afbd4&amp;name=68151-2780.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ERGOLOID MESYLATES 		
					</strong><br><span class="contentTableReg">dihydroergocornine mesylate, dihydroergocristine mesylate, dihydro-.alpha.-ergocryptine mesylate, and dihydro-.beta.-ergocryptine mesylate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68151-2780(NDC:53489-281)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Dihydroergocornine Mesylate</strong> (Dihydroergocornine) </td>
<td class="formItem">Dihydroergocornine Mesylate</td>
<td class="formItem">0.333 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Dihydroergocristine Mesylate</strong> (Dihydroergocristine) </td>
<td class="formItem">Dihydroergocristine Mesylate</td>
<td class="formItem">0.333 mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Dihydro-.alpha.-ergocryptine mesylate</strong> (Dihydro-.alpha.-ergocryptine) </td>
<td class="formItem">Dihydro-.alpha.-ergocryptine mesylate</td>
<td class="formItem">0.222 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Dihydro-.beta.-ergocryptine mesylate</strong> (Epicriptine) </td>
<td class="formItem">Dihydro-.beta.-ergocryptine mesylate</td>
<td class="formItem">0.111 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BUTYLATED HYDROXYANISOLE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROGENATED COTTONSEED OIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE K90</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MP;20</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68151-2780-0</td>
<td class="formItem">1  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA081113</td>
<td class="formItem">10/31/1991</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Carilion Materials Management
							(079239644)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Carilion Materials Management (079239644)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Carilion Materials Management</td>
<td class="formItem"></td>
<td class="formItem">079239644</td>
<td class="formItem">REPACK(68151-2780)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0df17d77-73b8-4c83-aa20-cd2eb684e6d4</div>
<div>Set id: 1344cf98-7d79-4ab4-9a63-2e632d9afbd4</div>
<div>Version: 2</div>
<div>Effective Time: 20120118</div>
</div>
</div> <div class="DistributorName">Carilion Materials Management</div></p>
</body></html>
